Global Kinetics' PKG being trialled in the UK


By Dylan Bushell-Embling
Tuesday, 30 September, 2014

Global Kinetics Corporation will provide its Parkinson’s KinetiGraph (PKG) devices for a 12-month pilot trial in the UK.

Parkinson's research and support charity Parkinson’s UK will enable access to the devices to up to 200 patients throughout the UK.

The PKG is a wrist-worn technology that automatically records specific movement data that can be used to inform dosing regimens and monitor symptoms.

Patients involved in the pilot program will wear the technology for 10 days prior to specialist consultation to allow information about their symptoms to be tracked.

“This is a new way of managing Parkinson’s and we eagerly await the outcome of this important evaluation program,” Parkinson’s UK CEO Steve Ford said.

“Mobile health technologies provide a new opportunity to monitor and manage this debilitating movement disorder affecting an estimated 127,000 people in the UK alone.”

Global Kinetics CEO Andrew Maxwell said he is confident that PKG will become a routine Parkinson’s management tool throughout the UK.

“We know this technology is highly effective at monitoring the key movement disorder symptoms of Parkinson’s, dyskinesia and bradykinesia,” he said. “When clinicians have this information, they can tailor medication regimes for optimal symptom management and ultimately enable improved quality of life.”

Related News

'Mini brains' mimic MS myelin damage

The MS organoids give researchers a highly detailed cellular view of myelin destruction...

Fast-aging placentas may contribute to pre-eclampsia

Placentas affected by pre-eclampsia show several signs of accelerated aging, including increased...

BioNTech opens mRNA manufacturing facility at La Trobe

Offering state-subsidised access to researchers and biotech startups, the facility aims to enable...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd